Investigating the role of APOC3 in heart and kidney diseases related to diabetes
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis
This study is looking at how a protein called APOC3 affects heart and kidney problems in people with diabetes, and it hopes to find out if blocking this protein can help prevent kidney disease, especially in those with both diabetes and kidney issues, which might raise the risk of heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10774240 on NIH RePORTER |
What this research studies
This research focuses on understanding how apolipoprotein C3 (APOC3) contributes to heart and kidney diseases in people with diabetes. It aims to determine if blocking APOC3 can prevent diabetic kidney disease and if diabetes combined with kidney impairment increases APOC3 levels, leading to a higher risk of atherosclerosis. The study will utilize mouse models to test these hypotheses through specific targeting of APOC3 using innovative techniques. Patients may benefit from insights that could lead to new treatments for managing their conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with diabetes who are at risk for cardiovascular and kidney diseases.
Not a fit: Patients without diabetes or those who do not have any cardiovascular or kidney complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing heart and kidney complications in diabetic patients.
How similar studies have performed: Previous research has shown promising results in targeting APOC3 for cardiovascular conditions, suggesting potential success for this approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Kanter, Jenny E. — University of Washington
- Study coordinator: Kanter, Jenny E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.